DCIS Picked up in Screening, Fewer Invasive Cancers
Ongoing public debate about the harm caused by mammography screening through overdiagnosis has led to controversy over the value of screen detection and treatment of DCIS. A major question has been the extent to which diagnosis and treatment of DCIS may prevent the occurrence of invasive breast cancer in the future.
For this study, researchers reviewed data on 5,243,658 women aged 50-64 who were screened over a four year period across 84 screening units in the UK's National Health Service Breast Screening Programme in England, Wales and Northern Ireland.
The researchers found that increased prior screen detection of DCIS was associated with a reduction in invasive cancers occurring in the subsequent three-year interval. In 90 percent of the screening units, for every three screen-detected cases of DCIS, there was one fewer case of invasive cancer in the following three years.
See Also - Study: High-Grade DCIS Detection Increases with Age
"There has been controversy over whether ductal carcinoma in situ will ever become invasive cancer. This is the first study from the screening programme which suggests that a substantial proportion of DCIS will become invasive if untreated, and it is therefore worth detecting and treating early," says lead researcher Professor Stephen Duffy from QMUL. "People can be reassured that detection of DCIS in the breast screening programme is benefitting the patients."
The findings suggest that, overall, detection and treatment of DCIS is worthwhile in the prevention of subsequent invasive disease. The authors note, however, that it cannot be known for certain what the outcome would have been for any individual DCIS if it had not been treated.
The average rate of DCIS detected at screening was 1.6 per 1,000 women screened, while the subsequent average rate of invasive cancers found within 36 months of their last screen was 2.9 per 1,000 screened.
The retrospective study was funded by the Department of Health Policy Research Programme and NHS Cancer Screening Programmes.
Source: Queen Mary University of London
Image credit: Wikimedia Commons
Published on : Mon, 7 Dec 2015
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether...
A breakthrough in biopsy efficiency The Brevera system streamlines the entire breast biopsy process from start to finish – with real-time imaging for instant verification and automated post-biopsy specimen handling. This has the potential to...
Redefining the Vision of Cardiovascular The LISENDO 880 is Hitachi’s premium 2D/4D diagnostic ultrasound solution for cardiologists in any clinical setting. The LISENDO 880 platform is redefining the vision for cardiac ultrasound by providing exceptional...
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...